

Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling


Basil K Williams, Jr, MD¹, Jennifer J Siegel, PhD², Katherina M Alsina, PhD², Lauren Johnston, MSW³, Amanda Sisco, MA⁴, Kyleigh LiPira, MBA³, Sara M Selig, MD, MPH³, and Peter G Hovland, MD, PhD⁴

¹University of Cincinnati College of Medicine, Cincinnati, OH, USA ²Castle Biosciences, Inc., Friendswood, TX, USA ³Melanoma Research Foundation, Washington, DC, USA ⁴Colorado Retina Associates, Denver, CO, USA

› **Conflicts of interest disclosure:** *JJS and KMA are employee shareholders of Castle Biosciences, Inc. (CBI). BKW is a consultant for Allergan, Genentech, and CBI. PGH is a consultant for CBI. Neither BKW nor PGH received payment in relation to this study. All other authors have nothing to declare*


➤ Background and Survey Study Design

- › Prognostic tests including 15-gene expression profile (15-GEP), chromosome 3 status, and BAP1 mutations are used across the U.S in the management of newly diagnosed uveal melanoma (UM)
- › The objective of this study was to understand UM patient experiences following 15-GEP testing compared to patients with alternative or no prognostic testing




➤ Desire For and Use of Prognostic Testing

A. 'Did you want prognostic information when diagnosed?'



N=177



B. 'What kind of testing was performed?'



› Patients Value Test Results: 'What do you feel you gained MOST...?'



› ...from any prognostic test:
increased knowledge and understanding

› ...from 15-GEP: patients with a Class 1A result (**low risk**) gained a sense of relief from uncertainty about the future



Low Decision Regret¹ After Prognostic Testing, Regardless of 15-GEP Class Result

- Patients had significantly more decision regret if they opted out of prognostic testing
- For 15-GEP-tested patients, no significant difference in decision regret was found across all Class results



¹Decision Regret Scale: AM O'Connor, 1996.